Celmatix Opens Up Lab in Brooklyn, Taps Diagnostics Pioneer as Chief Clinical Laboratory Officer

Celmatix Opens Lab in Brooklyn, Names Molecular Diagnostics Pioneer Daniel Farkas as Chief Clinical Laboratory Officer
Farkas Charged with Establishing Clinical Laboratory as Company Prepares to Release World's First Genetic Screen for Fertility Disorders

NEW YORK--(BUSINESS WIRE)--

Celmatix, a personalized medicine company focused on women's health and fertility, today announced that Dr. Daniel H. Farkas has joined the company as Chief Clinical Laboratory Officer. Dr. Farkas is charged with establishing Celmatix's new clinical laboratory, as the company prepares to launch the world's first genetic testing panel for fertility disorders.

Dr. Farkas, a genomics pioneer and established clinical laboratory director, brings decades of experience in molecular diagnostics to Celmatix. Most recently, Dr. Farkas was the lead laboratory director at Sequenom's (SQMN) clinical reference laboratories located in San Diego, CA, Grand Rapids, MI, and Morrisville, NC. He was the first professional to be certified in molecular diagnostics by the American Board of Bioanalysis and has helped establish best practices in molecular pathology through his tenure on the College of American Pathologists (CAP) Molecular Pathology Resource Committee. He also previously served as President of the Association for Molecular Pathology (AMP) and is a recipient of its Leadership Award. Celmatix is leveraging Dr. Farkas' vast experience to lead the development of a new laboratory space in Brooklyn, which will be the site of its sequencing operations connected to the genetic test.

"Dr. Farkas is one of the most accomplished laboratory directors in the industry and having him on board to oversee two company milestones – the opening of our first clinical laboratory and the release of our genetic test – is a huge boon for both our company and the industry," said Dr. Piraye Yurttas Beim, CEO and founder of Celmatix. "His move demonstrates the type of experienced talent that Celmatix, and other New York-based biotech companies, are capable of attracting. We look forward to more advancements with him at the helm of our laboratory efforts."

"I have seen molecular diagnostics travel through different medical specialties in waves. Celmatix is poised to transform another specialty, reproductive medicine, by bringing its science and technology to fertility specialists in a way that's never been done before. I am eager to be a part of that," said Farkas. "The biotech industry in New York, my hometown, is experiencing tremendous growth and Celmatix is at the vanguard. It's the perfect time to join a company poised to bring important new tools to a group of patients that will benefit from precision medicine."

About Celmatix
Celmatix is a personalized medicine company that uses big data and predictive analytics to help individuals who are struggling to have a baby make informed decisions. Founded in 2009 and based in New York City, Celmatix is disrupting the way women approach their lifelong fertility journey by empowering them through science and technology. The company's flagship Polaris product, in use at top fertility clinics across the country, is the world's first analytics platform for optimizing fertility. Celmatix also has an active research and development program dedicated to decoding the genetic basis of fertility potential. For more information, visit www.celmatix.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150811005345/en/

Health Care Industry
molecular diagnostics
Clinical Laboratory

Contact:
for Celmatix
Casey Walters, 310-464-6348
[email protected]

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.